Table 1.
Baseline characteristics
| Demographics | |
|---|---|
| Age (years) | 70 (10) |
| Male—no. (%) | 91 (76) |
| Female—no. (%) | 29 (24) |
| Weight (kg) | 86.8 (19.9) |
| Height (m) | 1.7 (0.1) |
| BMI (kg/m2) | 30.2 (6.4) |
| Waist circumference (cm) | 102.3 (16.3) |
| Hip circumference (cm) | 106.9 (14.0) |
| SBP (mm Hg) | 126 (23) |
| HR (beats/min) | 68 (13) |
| Medical history | |
|---|---|
| NYHA I—no. (%) | 34 (28) |
| NYHA II—no. (%) | 71 (59) |
| NYHA III—no. (%) | 15 (13) |
| Atrial fibrillation (%) | 37 (31) |
| Hypertension (%) | 63 (53) |
| Ischaemic heart disease (%) | 78 (65) |
| Diabetes (%) | 40 (33) |
| Previous cancer (%) | 16 (13) |
| Medication | |
|---|---|
| ACE‐I (%) | 86 (72) |
| ARB (%) | 27 (23) |
| Beta blocker (%) | 101 (84) |
| Loop diuretic (%) | 71 (59) |
| Blood results | |
|---|---|
| Urea (mmol/L) | 6.5 (5.3–9.5) |
| Creatinine (μmol/L) | 95 (80–118) |
| Bilirubin (μmol/L) | 16 (7) |
| Albumin (g/L) | 40 (3) |
| NTproBNP (ng/L) | 845 (355–1,368) |
| Echocardiography | |
|---|---|
| LVEDV (ml) | 139 (52) |
| LVEF (%) | 44 (14) |
| LAD (cm) | 4.0 (0.7) |
| TAPSE (mm) | 18 (5) |
ACE‐I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; HR, heart rate; LAD, left atrial diameter; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; NTproBNP, N‐terminal pro B‐type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion.
Continuous variables are shown as mean (standard deviation), categorical variables as percentage. NTproBNP is shown as median (Q1–Q3).